Andrew Aronsohn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew Aronsohn has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Donald Jensen
Center for Liver Disease, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medical Center, Chicago, IL
5 shared publications- Donald M. Jensen
University of Chicago Medical Center
3 shared publications A. Digiacomo
Divisione di Medicina Interna Ospedale Regina Margherita Comiso Italy
1 shared publicationA. Orlandini
Azienda Ospedaliero‐Universitaria di Parma Parma Italy
1 shared publicationAaron Cohn
Department of Medicine, University of Chicago Medical Center, Chicago, USA
1 shared publicationAasld‐Idsa Hcv Guidance
1 shared publication
Latest Publications
- 1 January 2024
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 23 (1) , e0242
Ethics and downstream effects of travel for transplant in the United States
- 1 January 2024
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 23 (1) , e0242
Ethics and downstream effects of travel for transplant in the United States
- Open Access
- 1 December 2018
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 12 (6) , 170-172
PRO: Needle Exchange Programs Should Be Instituted to Reduce Hepatitis C Virus Transmission†
- 1 December 2018
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 12 (6) , 170-172
Open AccessPRO: Needle Exchange Programs Should Be Instituted to Reduce Hepatitis C Virus Transmission†
- 1 September 2015
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 22 (5) , 352-360
Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease
- 1 September 2015
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 22 (5) , 352-360
Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease
- 6 March 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (10) , 3130-3135
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?
Zinc deficiency has been observed in cirrhosis, but management guidelines do not address screening for zinc deficiency. We aim to determine the prevalence of zinc deficiency in different stages of cirrhosis and to correlate zinc levels with complications of cirrhosis and clinical outcomes. Patients who had a diagnosis of cirrhosis and had serum zinc levels drawn from 2007 to 2011 were identified. Demographics, laboratory data, presence of ascites, encephalopathy, and infection were obtained; Child–Pugh and MELD scores were calculated. Stata software was used for data analysis. A total of 163 patients were included in the study. The median serum zinc level was 0.47 mcg/ml (IQR 0.37–0.63); 83 % of patients were zinc deficient. Zinc deficiency was more prevalent in patients with Child–Pugh score B or C, and with MELD scores ≥15. Zinc levels were lower in alcoholic, hepatitis C, and cholestatic diseases than in other etiologies of liver disease. Zinc levels correlated with INR (r = −0.56, p < 0.001), bilirubin (r = −0.51, p < 0.001), and albumin (r = 0.68, p < 0.001), and were lower in patients with ascites (0.40 vs. 0.57 mcg/ml, p < 0.001), encephalopathy (0.40 vs. 0.53 mcg/ml, p < 0.001), diuretic use (0.45 vs. 0.535 mcg/ml, p = 0.005), and infection (0.32 vs. 0.51 mcg/ml, p < 0.001). Ascites (p = 0.044) and infection (p = 0.009) were independently associated with zinc levels. Zinc-deficient patients had lower transplant-free survival rates than non-deficient patients. Zinc deficiency is highly prevalent in cirrhotic patients with Child–Pugh score B or C, and with MELD score ≥15. Zinc deficiency also correlates with disease severity, infection, and a worse transplant-free survival. Screening for zinc deficiency should be considered in this subset of patients.
- 6 March 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 60 (10) , 3130-3135
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?
Zinc deficiency has been observed in cirrhosis, but management guidelines do not address screening for zinc deficiency. We aim to determine the prevalence of zinc deficiency in different stages of cirrhosis and to correlate zinc levels with complications of cirrhosis and clinical outcomes. Patients who had a diagnosis of cirrhosis and had serum zinc levels drawn from 2007 to 2011 were identified. Demographics, laboratory data, presence of ascites, encephalopathy, and infection were obtained; Child–Pugh and MELD scores were calculated. Stata software was used for data analysis. A total of 163 patients were included in the study. The median serum zinc level was 0.47 mcg/ml (IQR 0.37–0.63); 83 % of patients were zinc deficient. Zinc deficiency was more prevalent in patients with Child–Pugh score B or C, and with MELD scores ≥15. Zinc levels were lower in alcoholic, hepatitis C, and cholestatic diseases than in other etiologies of liver disease. Zinc levels correlated with INR (r = −0.56, p < 0.001), bilirubin (r = −0.51, p < 0.001), and albumin (r = 0.68, p < 0.001), and were lower in patients with ascites (0.40 vs. 0.57 mcg/ml, p < 0.001), encephalopathy (0.40 vs. 0.53 mcg/ml, p < 0.001), diuretic use (0.45 vs. 0.535 mcg/ml, p = 0.005), and infection (0.32 vs. 0.51 mcg/ml, p < 0.001). Ascites (p = 0.044) and infection (p = 0.009) were independently associated with zinc levels. Zinc-deficient patients had lower transplant-free survival rates than non-deficient patients. Zinc deficiency is highly prevalent in cirrhotic patients with Child–Pugh score B or C, and with MELD score ≥15. Zinc deficiency also correlates with disease severity, infection, and a worse transplant-free survival. Screening for zinc deficiency should be considered in this subset of patients.
- Open Access
- 21 October 2013
- Published by Wolters Kluwer Health in Hepatology
- Vol. 59 (5) , 1688-1691
Preparing for the Uncertain Yet Inevitable: Off-Label Combinations of Antiviral Agents in Hepatitis C Virus
- 21 October 2013
- Published by Wolters Kluwer Health in Hepatology
- Vol. 59 (5) , 1688-1691
Open AccessPreparing for the Uncertain Yet Inevitable: Off-Label Combinations of Antiviral Agents in Hepatitis C Virus
- 17 October 2013
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 21 (5) , 377-380
Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort
Summary: The population of patients with chronic hepatitis C viral infection is ageing; however, elderly, hepatitis C‐infected patients are understudied and less frequently treated. This subanalysis of data from the multinational PROPHESYS study examined associations between age (≤65 vs >65 years), on‐treatment virological response and sustained virological response (SVR) in patients treated with peginterferon alfa‐2a (40KD)/ribavirin in accordance with local licences. PROPHESYS comprised three cohorts studied in 19 countries according to country‐specific legal and regulatory requirements. This subanalysis includes treatment‐naive HCV mono‐infected patients assigned to receive peginterferon alfa‐2a (40KD)/ribavirin, with 6276 individuals aged ≤65 years and 349 aged >65 years. Rapid virological response (RVR) rates by Week 4 were consistently lower in older genotype (G) 1 (21.6% vs 27.2% in younger patients), G2 (80.7% vs 85.1%) and G3 (60.0% vs 74.2%) patients. SVR rates were significantly lower (29.8% vs 43.0%) and relapse rates significantly higher (43.1% vs 26.7%) in older G1 patients (P = 0.0002 vs ≤65 years). In contrast, SVR and relapse rates were similar in G2 and G3 patients regardless of age. The positive predictive value of RVR for SVR was comparable in older and younger G1 patients (66.7% vs 68.6%, respectively) and higher in older G2 (80.7% vs 75.6%) and G3 (77.8% vs 66.8%) patients. Virological response rates are generally lower in elderly CHC patients, and RVR is a reliable positive predictor of SVR in patients >65 years.
- 17 October 2013
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 21 (5) , 377-380
Impact of age on viral kinetics of peginterferon alfa‐2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort
Summary: The population of patients with chronic hepatitis C viral infection is ageing; however, elderly, hepatitis C‐infected patients are understudied and less frequently treated. This subanalysis of data from the multinational PROPHESYS study examined associations between age (≤65 vs >65 years), on‐treatment virological response and sustained virological response (SVR) in patients treated with peginterferon alfa‐2a (40KD)/ribavirin in accordance with local licences. PROPHESYS comprised three cohorts studied in 19 countries according to country‐specific legal and regulatory requirements. This subanalysis includes treatment‐naive HCV mono‐infected patients assigned to receive peginterferon alfa‐2a (40KD)/ribavirin, with 6276 individuals aged ≤65 years and 349 aged >65 years. Rapid virological response (RVR) rates by Week 4 were consistently lower in older genotype (G) 1 (21.6% vs 27.2% in younger patients), G2 (80.7% vs 85.1%) and G3 (60.0% vs 74.2%) patients. SVR rates were significantly lower (29.8% vs 43.0%) and relapse rates significantly higher (43.1% vs 26.7%) in older G1 patients (P = 0.0002 vs ≤65 years). In contrast, SVR and relapse rates were similar in G2 and G3 patients regardless of age. The positive predictive value of RVR for SVR was comparable in older and younger G1 patients (66.7% vs 68.6%, respectively) and higher in older G2 (80.7% vs 75.6%) and G3 (77.8% vs 66.8%) patients. Virological response rates are generally lower in elderly CHC patients, and RVR is a reliable positive predictor of SVR in patients >65 years.
- Open Access
- 20 June 2013
- Published by Wolters Kluwer Health in Hepatology
- Vol. 59 (1) , 13-15
Expanding access to hepatitis C virus care: A call to deconstruct individualized therapy
- 20 June 2013
- Published by Wolters Kluwer Health in Hepatology
- Vol. 59 (1) , 13-15
Open AccessExpanding access to hepatitis C virus care: A call to deconstruct individualized therapy
- 19 March 2013
- Published by Springer Nature in Current Hepatology Reports
- Vol. 12 (1) , 7-12
HCV Therapy: Treat now or wait?
- 19 March 2013
- Published by Springer Nature in Current Hepatology Reports
- Vol. 12 (1) , 7-12
HCV Therapy: Treat now or wait?